Shimon Efrat

Prof. Shimon Efrat

orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
OBOri Bar-Nur
Ori Bar-Nur
HRHolger A. Russ
Holger A. Russ
SEShimon Efrat
Shimon Efrat
NBNissim Benvenisty
Nissim Benvenisty

1 December 1988 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SEShimon Efrat
Shimon Efrat
SLS Linde
S Linde
HKH Kofod
H Kofod
DSD Spector
D Spector
MDM Delannoy
M Delannoy
SBS Baekkeskov
S Baekkeskov
Three pancreatic beta-cell lines have been established from insulinomas derived from transgenic mice carrying a hybrid insulin-promoted simian virus 40 tumor antigen gene. The beta tumor cell (beta TC) lines maintain the features of differentiated beta cells for about 50 passages in culture. The cells produce both proinsulin I and II and efficiently process each into mature insulin, in a manner comparable to normal beta cells in isolated islets. Electron microscopy reveals typical beta-cell type secretory granules, in which insulin is stored. Insulin secretion is inducible up to 30-fold by glucose, although with a lower threshold for maximal stimulation than that for normal beta cells. beta TC lines can be repeatedly derived from primary beta-cell tumors that heritably arise in the transgenic mice. Thus, targeted expression of an oncogene with a cell-specific regulatory element can be used both to immortalize a rare cell type and to provide a selection for the maintenance of its differentiated phenotype.

5 July 2007 in Stem Cells
Verified
Journal Article
Closed access
PDF file
OKOhad Karnieli
Ohad Karnieli
YIYael Izhar-Prato
Yael Izhar-Prato
SBShlomo Bulvik
Shlomo Bulvik
SEShimon Efrat
Shimon Efrat
β Cell replacement is a promising approach for treatment of type 1 diabetes; however, it is limited by a shortage of pancreas donors. The pluripotent MSC in adult bone marrow (BM) offer an attractive source of stem cells for generation of surrogate β cells. BM-MSC can be obtained with relative ease from each patient, allowing potential circumvention of allograft rejection. Here, we report a procedure for expansion of BM-MSC in vitro and their differentiation into insulin-producing cells. The pancreatic duodenal homeobox 1 (Pdx1) gene was expressed in BM-MSC from 14 human donors, and the extent of differentiation of these cells toward the β-cell phenotype was evaluated. RNA and protein analyses documented the activation of expression of all four islet hormones. However, the cells lacked expression of NEUROD1, a key transcription factor in differentiated β cells. A significant insulin content, as well as glucose-stimulated insulin release, were demonstrated in vitro. Cell transplantation into streptozotocin-diabetic immunodeficient mice resulted in further differentiation, including induction of NEUROD1, and reduction of hyperglycemia. These findings were reproducible in BM-MSC from 9 of 14 donors of both sexes, ages 19–62. These results suggest a therapeutic potential for PDX1-expressing BM-MSC in β-cell replacement in patients with type 1 diabetes. Disclosure of potential conflicts of interest is found at the end of this article.

19 May 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MZMichal Zalzman
Michal Zalzman
SGSanjeev Gupta
Sanjeev Gupta
RGRanjit K. Giri
Ranjit K. Giri
IBIrina Berkovich
Irina Berkovich
BSBaljit S. Sappal
Baljit S. Sappal
SEShimon Efrat
Shimon Efrat
Beta-cell replacement is considered to be the most promising approach for treatment of type 1 diabetes. Its application on a large scale is hindered by a shortage of cells for transplantation. Activation of insulin expression, storage, and regulated secretion in stem/progenitor cells offers novel ways to overcome this shortage. We explored whether fetal human progenitor liver cells (FH) could be induced to differentiate into insulin-producing cells after expression of the pancreatic duodenal homeobox 1 (Pdx1) gene, which is a key regulator of pancreatic development and insulin expression in beta cells. FH cells possess a considerable replication capacity, and this was further extended by introduction of the gene for the catalytic subunit of human telomerase. Immortalized FH cells expressing Pdx1 activated multiple beta-cell genes, produced and stored considerable amounts of insulin, and released insulin in a regulated manner in response to glucose. When transplanted into hyperglycemic immunodeficient mice, the cells restored and maintained euglycemia for prolonged periods. Quantitation of human C-peptide in the mouse serum confirmed that the glycemia was normalized by the transplanted human cells. This approach offers the potential of a novel source of cells for transplantation into patients with type 1 diabetes.

11 April 1995 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SEShimon Efrat
Shimon Efrat
DFD Fusco-DeMane
D Fusco-DeMane
HLH Lemberg
H Lemberg
OEO al Emran
O al Emran
XWX Wang
X Wang
Conditional oncogene expression in transgenic mice is of interest for studying the oncoprotein requirements during tumorigenesis and for deriving cell lines that can be induced to undergo growth arrest and enhance their differentiated functions. We utilized the bacterial tetracycline (Tet)-resistance operon regulatory system (tet) from Tn10 of Escherichia coli to control simian virus 40 (SV40) large tumor (T) antigen (TAg) gene expression and to generate conditionally transformed pancreatic beta cells in transgenic mice. A fusion protein containing the tet repressor (tetR) and the activating domain of the herpes simplex virus protein VP16, which converts the repressor into a transcription activator, was produced in beta cells of transgenic mice under control of the insulin promoter. In a separate lineage of transgenic mice, the TAg gene was introduced under control of a tandem array of tet operator sequences and a minimal promoter, which by itself is not sufficient for gene expression. Mice from the two lineages were then crossed to generate double-transgenic mice. Expression of the tetR fusion protein in beta cells activated TAg transcription, resulting in the development of beta-cell tumors. Tumors arising in the absence of Tet were cultured to derive a stable beta-cell line. Cell incubation in the presence of Tet led to inhibition of proliferation, as shown by decreased BrdUrd and [3H]thymidine incorporation. The Tet derivative anhydrotetracycline showed a 100-fold stronger inhibition compared with Tet. When administered in vivo, Tet efficiently inhibited beta-cell proliferation. These findings indicate that transformed beta cells selected for growth during a tumorigenesis process in vivo maintain a dependence on the continuous presence of the TAg oncoprotein for their proliferation. This system provides an approach for generation of beta-cell lines for cell therapy of diabetes as well as conditionally transformed cell lines from other cell types of interest.

19 October 2004 in Biochemistry
Verified
Journal Article
Closed access
YPYair Porat
Yair Porat
YMYariv Mazor
Yariv Mazor
SEShimon Efrat
Shimon Efrat
EGEhud Gazit
Ehud Gazit